197 related articles for article (PubMed ID: 23924796)
21. Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model-Support for a Biologics License Application Submission: Part I.
Martinez JM; Brunet A; Hurbin F; DiCioccio AT; Rauch C; Fabre D
Clin Pharmacokinet; 2019 Jan; 58(1):101-113. PubMed ID: 29725996
[TBL] [Abstract][Full Text] [Related]
22. Capacity limits of asialoglycoprotein receptor-mediated liver targeting.
Bon C; Hofer T; Bousquet-Mélou A; Davies MR; Krippendorff BF
MAbs; 2017; 9(8):1360-1369. PubMed ID: 28876162
[TBL] [Abstract][Full Text] [Related]
23. Mathematical model of viral kinetics in vitro estimates the number of E2-CD81 complexes necessary for hepatitis C virus entry.
Padmanabhan P; Dixit NM
PLoS Comput Biol; 2011 Dec; 7(12):e1002307. PubMed ID: 22174670
[TBL] [Abstract][Full Text] [Related]
24. General Pharmacokinetic Features of Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Simulation-Based Study.
Bach T; Jiang Y; Zhang X; An G
J Clin Pharmacol; 2019 Mar; 59(3):394-405. PubMed ID: 30387863
[TBL] [Abstract][Full Text] [Related]
25. Incorporating Pharmacological Target-Mediated Drug Disposition (TMDD) in a Whole-Body Physiologically Based Pharmacokinetic (PBPK) Model of Linagliptin in Rat and Scale-up to Human.
Wu N; An G
AAPS J; 2020 Sep; 22(6):125. PubMed ID: 32996028
[TBL] [Abstract][Full Text] [Related]
26. Preclinical characterization of the ADME properties of a surrogate anti-IL-36R monoclonal antibody antagonist in mouse serum and tissues.
Conner KP; Pastuskovas CV; Soto M; Thomas VA; Wagner M; Rock DA
MAbs; 2020; 12(1):1746520. PubMed ID: 32310023
[TBL] [Abstract][Full Text] [Related]
27. Target-mediated exposure enhancement: a previously unexplored limit of TMDD.
Glassman PM; Muzykantov VR
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):411-420. PubMed ID: 32488574
[TBL] [Abstract][Full Text] [Related]
28. Hepatocyte permissiveness to Plasmodium infection is conveyed by a short and structurally conserved region of the CD81 large extracellular domain.
Yalaoui S; Zougbédé S; Charrin S; Silvie O; Arduise C; Farhati K; Boucheix C; Mazier D; Rubinstein E; Froissard P
PLoS Pathog; 2008 Feb; 4(2):e1000010. PubMed ID: 18389082
[TBL] [Abstract][Full Text] [Related]
29. Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2.
Lee WS; Shim SR; Lee SY; Yoo JS; Cho SK
Drug Des Devel Ther; 2018; 12():495-504. PubMed ID: 29563774
[TBL] [Abstract][Full Text] [Related]
30. Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice.
Kamath AV; Yip V; Gupta P; Boswell CA; Bumbaca D; Haughney P; Castro J; Tsai SP; Pacheco G; Ross S; Yan M; Damico-Beyer LA; Khawli L; Shen BQ
MAbs; 2014; 6(6):1631-7. PubMed ID: 25484068
[TBL] [Abstract][Full Text] [Related]
31. Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.
Ramanathan A; Gusarova V; Stahl N; Gurnett-Bander A; Kyratsous CA
PLoS One; 2016; 11(4):e0154498. PubMed ID: 27115873
[TBL] [Abstract][Full Text] [Related]
32. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis.
Betts AM; Clark TH; Yang J; Treadway JL; Li M; Giovanelli MA; Abdiche Y; Stone DM; Paralkar VM
J Pharmacol Exp Ther; 2010 Apr; 333(1):2-13. PubMed ID: 20089807
[TBL] [Abstract][Full Text] [Related]
33. Prevention of hepatitis C virus infection and spread in human liver chimeric mice by an anti-CD81 monoclonal antibody.
Ji C; Liu Y; Pamulapati C; Bohini S; Fertig G; Schraeml M; Rubas W; Brandt M; Ries S; Ma H; Klumpp K
Hepatology; 2015 Apr; 61(4):1136-44. PubMed ID: 25417967
[TBL] [Abstract][Full Text] [Related]
34. Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition.
Singh AP; Krzyzanski W; Martin SW; Weber G; Betts A; Ahmad A; Abraham A; Zutshi A; Lin J; Singh P
AAPS J; 2015 Mar; 17(2):389-99. PubMed ID: 25445845
[TBL] [Abstract][Full Text] [Related]
35. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor.
Deng R; Bumbaca D; Pastuskovas CV; Boswell CA; West D; Cowan KJ; Chiu H; McBride J; Johnson C; Xin Y; Koeppen H; Leabman M; Iyer S
MAbs; 2016; 8(3):593-603. PubMed ID: 26918260
[TBL] [Abstract][Full Text] [Related]
36. Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells.
Mazzocca A; Sciammetta SC; Carloni V; Cosmi L; Annunziato F; Harada T; Abrignani S; Pinzani M
J Biol Chem; 2005 Mar; 280(12):11329-39. PubMed ID: 15611113
[TBL] [Abstract][Full Text] [Related]
37. Quantitative modeling predicts competitive advantages of a next generation anti-NKG2A monoclonal antibody over monalizumab for the treatment of cancer.
Spinosa P; Musial-Siwek M; Presler M; Betts A; Rosentrater E; Villali J; Wille L; Zhao Y; McCaughtry T; Subramanian K; Liu H
CPT Pharmacometrics Syst Pharmacol; 2021 Mar; 10(3):220-229. PubMed ID: 33501768
[TBL] [Abstract][Full Text] [Related]
38. Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys.
Nnane IP; Han C; Jiao Q; Tam SH; Davis HM; Xu Z
Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):13-21. PubMed ID: 28132416
[TBL] [Abstract][Full Text] [Related]
39. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.
Datta-Mannan A; Lu J; Witcher DR; Leung D; Tang Y; Wroblewski VJ
MAbs; 2015; 7(6):1084-93. PubMed ID: 26337808
[TBL] [Abstract][Full Text] [Related]
40. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.
Fu J; Wang F; Dong LH; Zhang J; Deng CL; Wang XL; Xie XY; Zhang J; Deng RX; Zhang LB; Wu H; Feng H; Chen B; Song HF
Acta Pharmacol Sin; 2017 May; 38(5):710-718. PubMed ID: 28317872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
